The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated With Increased Secondary Infections
Open accessAbstract
BACKGROUND: Anti-inflammatory therapies such as IL-6 inhibition have been proposed for COVID-19 in a vacuum of evidence-based treatment. However, abrogating the inflammatory response in infectious diseases may impair a desired host response and predispose to secondary infections. METHODS: We retrospectively reviewed the medical record of critically ill COVID-19 patients during an 8-week span and compared the prevalence of secondary infection and outcomes in patients who did and did not receive tocilizumab. Additionally, we included representative histopathologic post-mortem findings from several COVID-19 cases that underwent autopsy at our institution. RESULTS: 111 patients were identified, of which 54 had received tocilizumab while 57 had not. Receiving tocilizumab was associated with a higher risk of secondary bacterial (48.1% vs. 28.1%, p=0.029 and fungal (5.6% vs. 0%, p=0.112) infections. Consistent with higher number of infections, patients who received tocilizumab had higher mortality (35.2% vs. 19.3%, p=0.020). Seven cases underwent autopsy. In 3 cases who received tocilizumab, there was evidence of pneumonia on pathology. Of the 4 cases that had not been given tocilizumab, 2 showed evidence of aspiration pneumonia and 2 exhibited diffuse alveolar damage. CONCLUSIONS: Experimental therapies are currently being applied to COVID-19 outside of clinical trials. Anti-inflammatory therapies such as anti-IL-6 therapy have the potential to impair viral clearance, predispose to secondary infection, and cause harm. We seek to raise physician awareness of these issues and highlight the need to better understand the immune response in COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Impaired immune and acute-phase responses in interleukin-6-deficient mice
Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., Zinkernagel, R., Bluethmann, H., & Köhler, G. (1994) · Nature · doi:10.1038/368339a0 · Cited by 1,768 · cited 1×
“Mice lacking IL-6 response have impaired immunity against viral, bacterial, and fungal pathogens (3).”
Background
Cited by
Garg, D., Muthu, V., Sehgal, I. S., Ramachandran, R., Kaur, H., Bhalla, A., Puri, G. D., Chakrabarti, A., & Agarwal, R. (2021) · Mycopathologia · doi:10.1007/s11046-021-00528-2 · Cited by 579
COVID-19-associated fungal infections
Hoenigl, M., Seidel, D., Sprute, R., Cunha, C., Oliverio, M., Goldman, G. H., Ibrahim, A. S., & Carvalho, A. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01172-2 · Cited by 482
Simons, D., Shahab, L., Brown, J., & Perski, O. (2021) · Addiction · doi:10.1111/add.15276 · Cited by 371
A metabolic handbook for the COVID-19 pandemic
Ayres, J. S. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0237-2 · Cited by 292
Viral sepsis: diagnosis, clinical features, pathogenesis, and clinical considerations
Xu, J.-Q., Zhang, W.-Y., Fu, J.-J., Fang, X.-Z., Gao, C.-G., Li, C., Yao, L., Li, Q.-L., Yang, X.-B., Ren, L.-H., et al. (2024) · Military Medical Research · doi:10.1186/s40779-024-00581-0 · Cited by 37
Metadata
- Authors
- Kimmig, L. M., Wu, D., Gold, M., Pettit, N. N., Pitrak, D., Mueller, J., Husain, A. N., Mutlu, E. A., & Mutlu, G. M.
- Venue
- Frontiers in Medicine
- Publisher
- Frontiers Media SA
- Published
- 2020-10-28
- Volume
- 7
- Pages
- 583897-583897
- ISSN
- 2296-858X (ISSN-L)
- OpenAlex
- W3097807388
- Cited by
- 182
- References
- 1
- FWCI
- 4.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated With Increased Secondary Infections. https://app.cochat.ai/papers/10.3389/fmed.2020.583897
- The paper
- Kimmig, L. M., Wu, D., Gold, M., Pettit, N. N., Pitrak, D., Mueller, J., Husain, A. N., Mutlu, E. A., & Mutlu, G. M. (2020). IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated With Increased Secondary Infections. Frontiers in Medicine. https://doi.org/10.3389/fmed.2020.583897
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.